Methods for producing and using extracellular vesicles derived from immune-tolerized fetal stem cells and application thereof for treating osteoarthritis

Extracellular vesicles derived from immunotolerized fetal stem cells, enriched with specific factors, address the limitations of current osteoarthritis treatments by promoting hyaline cartilage regeneration and reducing inflammation, providing a safe and effective therapeutic option.

JP2025129063APending Publication Date: 2025-09-03STEMMEDICARE
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2025027312
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-22
Filing Date
2025-02-21
Publication Date
2025-09-03

AI Technical Summary

Technical Problem

Current treatments for osteoarthritis, such as anti-inflammatory analgesics and hyaluronic acid injections, provide only temporary relief and have side effects, while allogeneic stem cell therapies risk immune rejection and limited efficacy, and existing extracellular vesicles derived from adult stem cells regenerate weaker hyaline cartilage and induce immune rejection.

Method used

A pharmaceutical composition using extracellular vesicles derived from immunotolerized fetal stem cells, enriched with specific growth factors, cytokines, and microRNAs, produced through a method involving co-culture of chondrocytes and mesenchymal stem cells, and trophoblast cells under pregnancy-like conditions, to promote hyaline cartilage regeneration and reduce inflammation without immune rejection.

Benefits of technology

The extracellular vesicles effectively deliver active ingredients to target cells, promoting hyaline cartilage regeneration and alleviating inflammation, serving as a fundamental osteoarthritis treatment without side effects, and are produced under conditions that ensure immune tolerance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2025129063000001_ABST
    Figure 2025129063000001_ABST
Patent Text Reader

Abstract

To provide pharmaceutical compositions for osteoarthritis treatment, comprising immune-tolerized fetal stem cell-derived extracellular vesicles containing various components that promote hyaline cartilage regeneration and relieve inflammation at higher levels than those stem cell-derived extracellular vesicles obtained under general culture conditions, and thus exhibiting superior hyaline cartilage regeneration and anti-inflammatory efficacy as well as methods for manufacturing the extracellular vesicles and compositions for osteoarthritis treatment using the extracellular vesicles.SOLUTION: These extracellular vesicles derived from immune-tolerized fetal stem cells contain fibroblast growth factor-2 (FGF-2), fibroblast growth factor-7 (FGF-7), insulin-like growth factor-1 (IGF-1), transforming growth factor-beta 1 (TGF-β1), bone morphogenetic protein-4 (BMP-4), bone morphogenetic protein-5 (BMP-5), and bone morphogenetic protein-7 (BMP-7) and HLA-G protein.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Use of bone marrow mesenchymal stem cell-derived exosomes in repairing articular cartilage deficiency

    EP4324469A1

  • Composition for induction of differentiation into chondrocytes or regeneration of cartilage tissue containing exosomes derived from stem cells differentiated into chondrocytes

    JP2018508486A

  • Mesenchymal stem cell-derived exosomes and use of the same

    JP2020152698A

  • Isolated septal cartilage exosomes used to generate cartilage tissue

    JP2022501034A

  • Method for producing extracellular vesicles containing fetal primal immunoglobulin

    JP2023515904A